Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency
November 10, 2021 08:00 ET
|
Mustang Bio, Inc.
Agreement expands Mustang’s pipeline of lentiviral gene therapies for SCID Preclinical development of additional targets to continue at Leiden University WORCESTER, Mass., Nov. 10, 2021...
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
November 04, 2021 09:24 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas
November 01, 2021 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio to Participate in Chardan’s Virtual 5th Annual Genetic Medicines Conference
September 30, 2021 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences
September 28, 2021 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio to Participate in Three September 2021 Investor Conferences
September 09, 2021 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
August 16, 2021 16:01 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology
August 12, 2021 16:45 ET
|
Mustang Bio, Inc.
The exclusively licensed platform has potential application for any tumor target Preclinical development to continue at Mayo Clinic Mustang to file IND upon identification of a lead CAR construct ...
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
August 02, 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive
June 17, 2021 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...